When zigzag lines or blind spots appear, you know a debilitating migraine is next. If you are tired of triptans leaving you feeling drugged, TMS Therapy for Migraine Headaches offers a different way forward. This handheld, drug-free device delivers a gentle pulse at the first sign of aura, stopping the pain before it takes over.
Pain elimination within 2 hours using single-pulse TMS during migraine with aura (pivotal FDA trial, Cerena TMS, n=201)
Reduction in monthly headache days when TMS used for preventive treatment (from 9.1 baseline) — Cephalalgia, International Headache Society
Pain-free rate at 2 hours with active TMS vs 22% with sham device in aura migraine study (randomized controlled trial)
Treatment per 24-hour maximum for TMS devices — not for unlimited daily use (FDA safety labeling)
Migraine with aura is not just a headache. The aura phase brings visual and sensory disturbances. Then the pain hits. The table below reflects what patients actually describe.
Symptom Domain
Visual aura
Sensory aura
Speech aura
Headache phase
Light sensitivity
Sound sensitivity
Nausea or vomiting
Postdrome
Common Impact
Zigzag lines, flashing lights, blind spots, or tunnel vision that lasts 5–60 minutes
Tingling or numbness spreading from fingertips to face, often on one side
Difficulty finding words, slurred speech, or trouble understanding conversation
Throbbing pain, usually one-sided, lasting 4–72 hours without treatment
Need to lie down in a dark room; phone screens feel unbearable
Ordinary noises (dog barking, dishwasher) feel physically painful
Stomach distress that makes oral medications impossible to keep down
Exhaustion, brain fog, and scalp tenderness that lingers after pain subsides
The biology of migraine aura. Migraine with aura begins with a phenomenon called cortical spreading depression (CSD). Think of it as a slow wave of altered electrical activity moving across the outer surface of the brain like a ripple in a pond. This wave causes the visual, sensory, or speech disturbances you experience as aura. Then that CSD wave triggers the pain-generating processes that produce the headache phase.
How TMS interrupts the process. Single-pulse TMS delivers a brief, focused magnetic pulse — approximately 0.9 Tesla, lasting less than a millisecond — to the occipital cortex at the back of your head. That pulse generates a small electrical current in the targeted brain tissue. That current disrupts the propagating CSD wave before it can trigger the headache phase. It also appears to alter connections between the cortex and deep brain centers that process pain signals.
Magnetic pulse strength: ~0.9 Tesla (MRI-strength, highly focused)
Target area: Occipital cortex (back of head, visual processing region)
Effect on CSD: Disrupts the abnormal electrical wave underlying aura
Effect on pain networks: Reduces excitability of circuits linking cortex to pain centers
Timing requirement: Must be applied during aura phase for acute treatment
For prevention. Regular daily pulses (typically four pulses twice daily) are believed to reduce overall cortical excitability. Your brain becomes less susceptible to initiating CSD waves in the first place.
TMS for migraine can be used in two distinct ways, depending on your migraine pattern and treatment goals.
Recognize aura onset — visual changes, zigzag lines, blind spots, or tingling in face or hands
Position the handheld device at the back of your head
Press activation button to deliver first pulse (less than 1 millisecond)
Wait 30 seconds then deliver second pulse
Do not repeat for at least 24 hours
What the data shows: In the pivotal FDA trial (201 patients with migraine with aura), 38% of patients who used TMS reported pain elimination within 2 hours, compared to 17% with sham devices. At 24 hours, 34% remained pain-free vs 10% with sham.
Use daily regardless of whether a migraine is occurring
Deliver four magnetic pulses twice daily on a fixed schedule
Continue ongoing regimen similar to preventive medications
What the data shows: In a study published in Cephalalgia (the journal of the International Headache Society), patients with high-frequency migraine (average 9.1 headache days per month at baseline) who used TMS preventively reduced headache days by 2.8 per month. No serious side effects were reported.
Feature
Mechanism
Systemic side effects
When to use
FDA clearance for migraine
Can be used at home
Insurance coverage
TMS for Migraine
Magnetic pulses disrupt cortical spreading depression
None
During aura OR daily prevention
✓ (migraine with aura)
✓ (Cerena, Spring TMS, eNeura)
Limited (often self-pay; some plans cover after prior authorization)
Triptans (Acute)
Serotonin (5-HT1B/1D) receptor agonist
Chest tightness, tingling, fatigue, nausea; contraindicated with cardiovascular disease
At onset of headache pain
✓ (multiple agents)
✓
✓ Routinely covered
Preventive Medications
Varies (beta-blockers, anticonvulsants, CGRP antibodies, antidepressants)
Weight gain, fatigue, brain fog, sexual dysfunction, constipation (CGRP agents)
Daily, regardless of symptoms
✓ (multiple agents including CGRP antibodies)
✓
✓ Routinely covered
Cefaly
Transcutaneous electrical stimulation of supraorbital nerve
None (local sensation only)
Daily preventive
✓ (preventive)
✓
Often self-pay ($300-500 device)
Common Side Effects (Typically Mild and Transient)
Scalp discomfort or tapping sensation at treatment site — Up to 40%
Mild headache after treatment — Up to 30%
Dizziness or lightheadedness — Occasional
Tingling sensation — Occasional
Ringing in ears (temporary) — Rare
The most common side effects are related to stimulation of branches of the trigeminal nerve and muscle tension. Some patients report that the first few sessions trigger a mild headache, which typically resolves as the brain adjusts to the stimulation.
Absolute Contraindications (Cannot Use TMS)
Metal implants in or near the head (excluding dental fillings and braces):
Aneurysm clips or coils
Cochlear implants
Brain stimulators
Metal plates or fragments in the skull
Shrapnel or bullet fragments near the head
Implanted electronic devices that could be disrupted by magnetic fields:
Cardiac pacemakers
Implanted defibrillators
History of epilepsy or seizure disorder
Relative Contraindications (Discuss with Dr. Sikowitz)
Personal or family history of seizures
Current medical conditions that lower seizure threshold (e.g., severe electrolyte imbalance, sleep deprivation, alcohol withdrawal)
Facial tattoos containing magnetic or metallic ink
Pregnancy (insufficient safety data; discuss risks vs benefits)
Seizure Risk
The most serious potential side effect is seizure, but this is very rare. The risk is approximately 1.4% in patients with epilepsy when aggressive high-frequency protocols are used. With standard TMS for migraine adhering to safety guidelines (single pulse, low intensity, proper screening), the risk is significantly lower.
NICE explicitly notes “uncertainty about the safety of long-term or frequent use of TMS.” The longest published follow-up studies span months, not years or decades.
Best outcomes occur when TMS is integrated with appropriate medication management, trigger identification, sleep hygiene, and lifestyle modifications. Discuss a comprehensive plan with Dr. Sikowitz.
If you miss the aura window or your migraine does not include clear, recognizable aura symptoms, TMS may not help that specific attack. The device has been described in clinical literature as ineffective when applied outside the aura phase.
In the FDA trial, 38% of patients became pain-free within 2 hours — that means 62% did not. Some patients get partial relief. Others get no relief. The device is not a guaranteed solution.
The average reduction was 2.8 headache days per month — meaningful for some patients, disappointing for others expecting complete elimination of migraines.
With limited insurance coverage, many patients pay thousands of dollars out-of-pocket for the device plus ongoing subscription fees. Before committing, ask: “Is a reduction of 2-3 headache days per month worth this cost for my situation?”
If you have migraine without aura, TMS is off-label for acute treatment. Clinicians may still use it off-label, but the evidence base is weaker.
One treatment per 24 hours maximum. You cannot use it for multiple migraine attacks on the same day. If you have cluster attacks or prolonged aura, this limit may be clinically significant.
Metal implants, pacemakers, and seizure disorders generally exclude patients from TMS for migraine. Proper screening is mandatory before purchase or use.
FDA clearance is specifically for migraine with aura. Some studies suggest benefit for migraine without aura, but evidence is stronger and more consistent for aura-type migraine. Patients without clear aura symptoms may not be candidates.
When used during the aura phase, TMS pulses take effect within minutes. The goal is to prevent the headache from developing. In the FDA trial, 38% of users reported pain elimination within 2 hours compared to 17% with sham. If you miss the aura window, the device may not help that specific attack.
Yes. TMS can be used alongside medications. However, if you take medications that lower seizure threshold (e.g., certain antidepressants, antipsychotics, or stimulants), discuss this with Dr. Sikowitz during evaluation.
Rarely. The risk is approximately 1.4% in patients with epilepsy when aggressive high-frequency protocols are used. With standard TMS for migraine adhering to safety guidelines (single pulse, low intensity, proper screening), the risk is extremely low. Patients with known epilepsy are generally excluded from standard migraine TMS protocols.
Some evidence supports TMS for chronic migraine. Studies have shown reduction in headache days, though the effect size is modest — typically a reduction of 2-3 headache days per month. Discuss your specific frequency and migraine characteristics with Dr. Sikowitz.
Yes. Handheld TMS devices (Cerena, Spring TMS, eNeura) are portable and designed for self-use at home, at work, or while traveling. The device is approximately the size of a small handheld scanner or a large smartphone. It requires battery power but no external connections.
Generally less consistently than TMS for depression. Many insurers consider it non-covered or experimental for migraine. However, coverage is improving. Contact our office for current insurance verification specific to your plan.
Yes. The TMS Center of New Jersey offers secure video telehealth for initial consultations and follow-up appointments. Device instruction may require in-person demonstration or video guidance depending on the specific device.
Response rates are not 100%. In the FDA trial, 38% became pain-free within 2 hours, meaning 62% did not achieve that outcome. Some patients get partial relief; others get none. Alternative options include continued medication management, other neuromodulation devices (Cefaly, Nerivio, gammaCore), or referral to a headache specialist.
Call Us:
(267) 214-1941
